London—Thin, shallow corneal flaps of approximately 80 to 90 ?m created with an IntraLase femtosecond laser (IntraLase Corp.) may produce the best results in refractive surgery, effectively eliminating pain and haze while producing long-term visual stability, said John Marshall, PhD, in a keynote address during a session on femtosecond lasers here at the XXIV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS).
The problem of tissue drag, which once plagued ophthalmic surgeons, is largely a thing of the past?thanks to groundbreaking work conducted several decades ago by Leonard Apt, MD, currently professor of ophthalmology at the Jules Stein Eye Institute, University of California, Los Angeles (UCLA).
This year's scientific program includes more than 500 peer-reviewed courses.
Madison, WI—Results from a recent study have shown for the first time the potential of anti-vascular endothelial growth factor (VEGF) therapy to improve features of diabetic retinopathy, according to Micheal M. Altaweel, MD.
About one-third of patients displayed improvement in visual acuity at 1, 2, and 3 months after injection.
Editor's Note: Part 1 of this two-part feature (see Ophthalmology Times, Sept. 15, 2006) presented a customer-focused approach for persuading patients to undergo LASIK or a premium cataract procedure. At the heart of this method is training staff to concentrate on identifying patients' needs and how to meet their expectations, rather than jumping to the cost or postsurgical outcomes.
Irvine, CA—Intravitreous dexamethasone in a biodegradable, extended-release implant (Posurdex, Allergan) produced significant improvements in visual acuity and was well tolerated in recent studies. Additional investigation comparing applicator versus incisional placement suggests that the applicator approach is quicker, is at least as safe, and results in similar outcomes, according to Baruch D. Kuppermann, MD, PhD.
Fort Lauderdale, FL—Multifocal visual evoked potentials (mfVEP) and standard automated perimetry (SAP) perform in a similar manner in eyes with high-risk ocular hypertension or early glaucoma, according to a comparison study. However, agreement between the two techniques reached only 80%, suggesting that they detect different defects in some cases, said Brad Fortune, OD, PhD, associate scientist, Discoveries in Sight, Devers Eye Institute, Portland, OR.
Fort Lauderdale, FL—A modified glaucoma valve made of a porous polymer material reduced outflow resistance in tests conducted in an animal model. The reduced resistance should in turn result in improved control of IOP over conventional implants, explained R. Rand Allingham, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Physicians have to convince patients of the long-term consequences of failing to take glaucoma medication by educating them about the disease and the risk of blindness.